By Brigette Honaker  |  January 28, 2022

Category: Legal News

older woman in bed reaching for glasses

There is no Beovu recall, but the FDA approved label changes regarding adverse eye problems in 2020 to better inform patients and doctors.

Beovu Eye Problems

Beovu (brolucizumab) is an eye injection used to treat wet age-related macular degeneration (AMD), an eye condition caused by leaking blood vessels in the eye. Symptoms of the condition include blurry vision and blind spots. If left untreated, wet AMD can cause severe vision loss.

Although patients aimed to prevent eye problems by agreeing to Beovu treatment, the drug may actually cause serious eye problems instead of fixing wet AMD vision loss.

Beovu is associated with various eye-related complications including retinal vasculitis and retinal vascular occlusion. Retinal vasculitis is the inflammation of blood vessels in the retina. Retinal vascular occlusion is a blockage of the same blood vessels in the retina. Both conditions can lead to vision disturbances and even permanent vision loss.

Has There Been a Beovu Recall?

There is no Beovu recall from Novartis or the U.S. Food and Drug Administration (FDA). However, the FDA approved safety label changes last year which better warn about the risks for adverse Beovu eye problems.

The updated label information includes specific information about the risks of retinal vasculitis and retinal vascular occlusion while taking Beovu.

“This label update provides clinicians with important information to guide treatment decisions. We believe Beovu continues to represent an important treatment option for patients with wet AMD, with an overall favorable benefit-risk profile,” Marcia Kayath, Novartis’ Global Head of Medical Affairs and Chief Medical Officer, said in a press release following the label change.

“As we proceed to examine root causes and potential mitigation strategies, we will continue to communicate findings with transparency and urgency to regulatory bodies and healthcare providers.”

Later in 2020, a Novartis safety review identified risk factors for Beovu eye problems, including previous intraocular inflammation or prior retinal vascular occlusion within 12 months of the first injection treatment.

doctor holding macular degeneration card While the risk rate for Beovu eye problems was 0.46% for all patients, people who suffered from the conditions listed above before treatment had a 3.97% risk rate for complications. Novartis changed Beovu’s safety profile and contraindications to reflect these risks.

In May 2021, after revealing one year results from a Phase III trial, Novartis prematurely ended two other safety trials due to the confirmation of Beovu’s link to eye inflammation and other problems. The trials aimed to explore more frequent dosing for Beovu patients and the safety and efficacy of more frequent doses. Other trials were continued, with Novartis reporting a “well-tolerated” safety profile.

Although the FDA has not announced a Beovu recall, the new label changes effectively warn both patients and doctors about the risks associated with the drug. However, while new Beovu patients may feel sufficiently warned about the risks, original patients may not have received the same forewarning.

Novartis faces lawsuits from consumers who claim that the company did not warn them about the potential of Beovu eye problems they suffered from after treatment. If you experienced these problems, you may be able to join other plaintiffs by taking legal action.

Free Beovu Vision Loss & Blindness Lawsuit Investigation Evaluation

If you suffered from any of the eye problems listed below after taking Beovu, you may be eligible to join a FREE Beovu side effects lawsuit investigation.

Common side effects include:

  • Retinal vasculitis
  • Retinal  vascular (vein) occlusion
  • Vision loss
  • Blindness

…or other vision problems.

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.


 

  • This field is for validation purposes and should be left unchanged.
  • This field is hidden when viewing the form
  • The law firm responsible for the content of this page is: The Wilkins Law Firm, PLLC
  • This investigation is for those who have used Beovu from October 2019 through August 2020. If you did not use Beovu, you will NOT qualify for this investigation.
  • Select all that apply.
  • Please estimate Month, Date, and Year to the best of your abilities (MM/DD/YYYY).
  • We tell you about cash you can claim every week! Subscribe to our free newsletter today.
  • This field is hidden when viewing the form

    By submitting information to Top Class Actions you agree that the information you submit, including your phone number and email address, will be shared with and used by Top Class Actions, The Wilkins Law Firm, PLLC, their agents, and their co-counsel, if any, to contact you. You understand that this authorization overrides any previous registrations on any federal or state Do Not Call registry(ies). While your communications with a lawyer may be subject to the attorney-client privilege, communications through this website may not be because Top Class Actions is not a law firm. Please do not share any confidential or privileged information through this website. Top Class Actions or the attorney(s) or their agent(s) with whom your information is shared may be ordered by a court of law to produce your information in certain legal situations. Also, you are not formally represented by a law firm unless and until a contract of representation is signed by you and the law firm.*

  • This field is hidden when viewing the form
    By checking this box, I consent to receive from Top Class Actions, and the lawyer, their agents or their co-counsel sponsoring this investigation, marketing emails, calls or texts sent by automatic telephone dialing systems, artificial/prerecorded voice messages, and/or otherwise. I understand that this authorization overrides any registrations on any Do Not Call registry(ies). I understand that consent is not a condition of purchase, and that I may opt out at any time. Review Top Class Actions’ Terms and Conditions and Privacy Policy here.

E-mail any problems with this form to:

[email protected].

Leave a Reply

Your email address will not be published. By submitting your comment and contact information, you agree to receive marketing emails from Top Class Actions regarding this and/or similar lawsuits or settlements, and/or to be contacted by an attorney or law firm to discuss the details of your potential case at no charge to you if you qualify. Required fields are marked *

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.